Hans Peter Schmid

Summary

Affiliation: St. Gallen
Country: Switzerland

Publications

  1. doi request reprint [Anti-inflammatory drugs and prostatic carcinoma: current state of evidence]
    H P Schmid
    Klinik für Urologie, Kantonsspital, St Gallen
    Aktuelle Urol 43:112-4. 2012
  2. ncbi request reprint Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation
    Hans Peter Schmid
    Department of Urology, Kantonsspital St Gallen, Switzerland
    Urol Int 79:95-104. 2007
  3. doi request reprint Growth hormone inhibitors in prostate cancer: a systematic analysis
    Hans Peter Schmid
    Department of Urology, Kantonsspital St Gallen, St Gallen, Switzerland
    Urol Int 81:17-22. 2008
  4. doi request reprint Nutritional aspects of primary prostate cancer prevention
    Hans Peter Schmid
    Department of Urology, St Gallen, Switzerland
    Recent Results Cancer Res 188:101-7. 2011
  5. doi request reprint [Introduction to the topic: current developments in urology in Switzerland]
    H P Schmid
    Klinik für Urologie, Kantonsspital, Rorschacher Strasse 95, CH 9007, St Gallen, Switzerland
    Urologe A 47:953-4. 2008
  6. ncbi request reprint Update on screening for prostate cancer with prostate-specific antigen
    Hans Peter Schmid
    Department of Urology, Kantonsspital, CH 9007 St Gallen, Switzerland
    Crit Rev Oncol Hematol 50:71-8. 2004
  7. ncbi request reprint Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma
    Hans Peter Schmid
    Department of Urology, Kantonsspital, St Gallen, Switzerland
    Eur Urol 43:28-30. 2003
  8. ncbi request reprint Accurate control of the superficial and deep dorsal veins during radical retropubic prostatectomy: the Münster clamp technique
    Hans Peter Schmid
    Department of Urology, Westfalische Wilhelms University, Munster, Germany
    Urol Int 70:151-3. 2003
  9. ncbi request reprint Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls
    Frank Oberpenning
    Department of Urology, University of Munster, Albert Schweitzer Str 33, D 48129 Munster, Germany
    Eur Urol 42:577-82; discussion 582. 2002
  10. ncbi request reprint A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer
    Frank Oberpenning
    Department of Urology, University of Munster, Munster, Germany
    Clin Chem Lab Med 41:90-4. 2003

Collaborators

Detail Information

Publications39

  1. doi request reprint [Anti-inflammatory drugs and prostatic carcinoma: current state of evidence]
    H P Schmid
    Klinik für Urologie, Kantonsspital, St Gallen
    Aktuelle Urol 43:112-4. 2012
    ..Studies are limited by inadequate information on dose and duration of use and by methodological biases. Furthermore, potential benefits should be weighed against the known side effects of long-term use...
  2. ncbi request reprint Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation
    Hans Peter Schmid
    Department of Urology, Kantonsspital St Gallen, Switzerland
    Urol Int 79:95-104. 2007
    ..To evaluate systematically the current endocrine treatment options for patients with biochemical recurrence after radical prostatectomy or radiation therapy for localized prostate cancer...
  3. doi request reprint Growth hormone inhibitors in prostate cancer: a systematic analysis
    Hans Peter Schmid
    Department of Urology, Kantonsspital St Gallen, St Gallen, Switzerland
    Urol Int 81:17-22. 2008
    ....
  4. doi request reprint Nutritional aspects of primary prostate cancer prevention
    Hans Peter Schmid
    Department of Urology, St Gallen, Switzerland
    Recent Results Cancer Res 188:101-7. 2011
    ..The trial was discontinued recently as there was no evidence of a benefit from either agent. Nevertheless, lifestyle changes could be recommended to men at risk for developing clinical prostate cancer...
  5. doi request reprint [Introduction to the topic: current developments in urology in Switzerland]
    H P Schmid
    Klinik für Urologie, Kantonsspital, Rorschacher Strasse 95, CH 9007, St Gallen, Switzerland
    Urologe A 47:953-4. 2008
  6. ncbi request reprint Update on screening for prostate cancer with prostate-specific antigen
    Hans Peter Schmid
    Department of Urology, Kantonsspital, CH 9007 St Gallen, Switzerland
    Crit Rev Oncol Hematol 50:71-8. 2004
    ..Several national and international prospective trials are currently being conducted to answer these important questions but results will only be available in a few years...
  7. ncbi request reprint Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma
    Hans Peter Schmid
    Department of Urology, Kantonsspital, St Gallen, Switzerland
    Eur Urol 43:28-30. 2003
    ..This makes objective evaluation of chemotherapeutic agents difficult. Prostate specific antigen (PSA) as a dynamic model was analyzed as potential auxiliary end point in HRPCa...
  8. ncbi request reprint Accurate control of the superficial and deep dorsal veins during radical retropubic prostatectomy: the Münster clamp technique
    Hans Peter Schmid
    Department of Urology, Westfalische Wilhelms University, Munster, Germany
    Urol Int 70:151-3. 2003
    ..To better control the superficial and deep dorsal veins during radical retropubic prostatectomy and, thus, to reduce blood loss...
  9. ncbi request reprint Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls
    Frank Oberpenning
    Department of Urology, University of Munster, Albert Schweitzer Str 33, D 48129 Munster, Germany
    Eur Urol 42:577-82; discussion 582. 2002
    ..We investigated the impact of interchanging free prostate specific antigen (f-PSA) concentrations from 10 different assays over a reference total PSA (t-PSA) on predicting prostate histology with free-to-total PSA ratios (f/t-PSA)...
  10. ncbi request reprint A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer
    Frank Oberpenning
    Department of Urology, University of Munster, Munster, Germany
    Clin Chem Lab Med 41:90-4. 2003
    ..These data provide additional evidence for clinical advantages of equimolar-response over nonequimolar-response PSA assay formats...
  11. ncbi request reprint Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation
    Ying Waeckerle-Men
    Research Department, Cantonal Hospital St Gallen, St Gallen, Switzerland
    Prostate 64:323-31. 2005
    ..In case of androgen-independent prostate cancer (CaP), the cancer itself, diverse prior therapies, and the hormone manipulation may affect the immune system...
  12. doi request reprint EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
    Axel Heidenreich
    Department of Urology, RWTH University Aachen, Aachen, Germany
    Eur Urol 59:61-71. 2011
    ..Our aim was to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically localised cancer of the prostate (PCa)...
  13. ncbi request reprint Multidisciplinary care in patients with prostate cancer: room for improvement
    Räto T Strebel
    Department of Urology, Kantonsspital Graubunden, Chur, Switzerland
    Support Care Cancer 21:2327-33. 2013
    ..We aimed to assess the current practices of multidisciplinarity and their possible implications in treatment management in Switzerland...
  14. ncbi request reprint Problems with prostate-specific antigen screening: a critical review
    Hans Peter Schmid
    Department of Urology, Kantonsspital, 9007 St Gallen, Switzerland
    Recent Results Cancer Res 163:226-31; discussion 264-6. 2003
    ..In the meantime, individual case finding (opportunistic screening) is recommended for men with a life-expectancy of at least 10 years...
  15. ncbi request reprint [Therapy and follow-up of bladder cancer]
    Daniel Meyer
    Klinik für Urologie, Kantonsspital St Gallen, St Gallen, Schweiz
    Wien Med Wochenschr 157:162-9. 2007
    ..For advanced and metastatic tumours, despite good response of bladder cancer to chemotherapy, prognosis is still poor. However, implementation of new chemotherapeutic agents indicate a trend towards improved survival rates...
  16. doi request reprint Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer
    Stephen Frederic Wyler
    Department of Urology, Kantonsspital St Gallen, St Gallen, Switzerland
    Urol Int 82:17-23. 2009
    ..To evaluate quality of life (QOL) after radical retropubic prostatectomy (RP) and low-dose-rate brachytherapy (BT)...
  17. ncbi request reprint Prostate biopsy in Switzerland: a representative survey on how Swiss urologists do it
    Thomas Leippold
    Department of Urology, Kantonsspital, St Gallen, Switzerland
    Scand J Urol Nephrol 42:18-23. 2008
    ..Therefore, a survey of all urologists in Switzerland was carried out to investigate indications, patient preparation and technique with regard to transrectal prostate biopsy...
  18. ncbi request reprint Prevention of prostate cancer: more questions than data
    Hans Peter Schmid
    Department of Urology, Kantonsspital, St Gallen, Switzerland
    Recent Results Cancer Res 174:101-7. 2007
    ..Until we have the results, lifestyle changes could be recommended to men at risk for developing clinical prostate cancer and 5-alpha-reductase inhibitors need to be discussed with men who are concerned about prostate cancer...
  19. doi request reprint [Urination disorders in the man: differential diagnoses and therapy of benign prostate syndrome]
    Daniel Meyer
    Klinik für Urologie, Kantonsspital St Gallen
    Praxis (Bern 1994) 102:1237-42. 2013
    ..In addition to neurogenic causes other urological differential diagnoses can be clarified and treated. If diagnosis of benign prostatic syndrome is confirmed, various medical and surgical treatment options are available. ..
  20. ncbi request reprint Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older men
    Hans Joachim Luboldt
    Department of Urology, University of Essen, Essen, Germany
    Urology 61:1177-80. 2003
    ..To investigate whether bicycle riding significantly alters total prostate-specific antigen (tPSA), free PSA (fPSA), and percent free PSA (%fPSA) serum concentrations in potential candidates for prostate cancer screening...
  21. ncbi request reprint High incidence of independent second malignancies after non-muscle-invasive bladder cancer
    Henrik Zecha
    Department of Urology, St Gallen Cantonal Hospital, St Gallen, Switzerland
    Scand J Urol Nephrol 45:245-50. 2011
    ..This study investigated the incidence of independent non-urothelial second malignancies and associated risk factors in patients with NMIBC...
  22. doi request reprint Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases
    Daniel S Engeler
    Department of Urology, St Gallen Cantonal Hospital, Switzerland
    Scand J Urol Nephrol 42:522-7. 2008
    ....
  23. ncbi request reprint Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer?
    Frank Oberpenning
    Department of Urology, University of Munster, Albert Schweitzer Str 33, D 48129, Munster, Germany
    Eur Urol 43:478-84. 2003
    ..A strip test for the semi-quantitative determination of prostate specific antigen (PSA) based on whole blood was evaluated by the Working Group on Laboratory Diagnostics of the German Urological Association...
  24. doi request reprint Therapeutic options for intractable hematuria in advanced bladder cancer
    Dominik Abt
    Department of Urology, St Gallen Cantonal Hospital, St Gallen, Switzerland
    Int J Urol 20:651-60. 2013
    ..Interventional radiology and alum instillation seem to be suitable alternative options for patients who, after critical consideration, cannot be treated by irrigation, transurethral resection or palliative cystectomy. ..
  25. ncbi request reprint Submucosal endocervicosis of the bladder: an ectopic, glandular structure of Müllerian origin
    Stefan Preusser
    Department of Urology, St Gallen Cantonal Hospital, St Gallen, Switzerland
    Scand J Urol Nephrol 42:88-90. 2008
    ..Transurethral biopsy of the tumor confirmed the diagnosis of endocervicosis. Complete transurethral resection was rejected due to the absence of symptoms and the benign condition of the lesion...
  26. ncbi request reprint Late recurrence of adenoid cystic carcinoma of the prostate
    Hans Peter Schmid
    Department of Urology, Westfalische Wilhelms University, Munster, Germany
    Scand J Urol Nephrol 36:158-9. 2002
    ..The current follow up comprises 9 years and 5 months at which the patient is asymptomatic with stable disease. Lymph node or distant metastases did never occur and the prostate specific antigen level was always within the normal range...
  27. ncbi request reprint A double-blind, placebo controlled comparison of the morphine sparing effect of oral rofecoxib and diclofenac for acute renal colic
    Daniel S Engeler
    Department of Urology, St Gallen Cantonal Hospital, Switzerland
    J Urol 174:933-6. 2005
    ..We compared the morphine sparing effect of a single dose of 50 mg oral rofecoxib, 3, 8-hourly doses of 50 mg diclofenac and placebo for acute renal colic...
  28. ncbi request reprint Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
    Ying Waeckerle-Men
    Research Department, Cantonal Hospital St Gallen, 9007, St Gallen, Switzerland
    Cancer Immunol Immunother 55:1524-33. 2006
    ..In this trial, we determined the immunostimulatory capacity of autologous DC pulsed with multiple T cell epitopes derived from four different prostate-specific antigens in patients with advanced hormone-refractory prostate cancer...
  29. ncbi request reprint Intermittent ureteral herniation--rare cause of flank pain
    Waltraud M Remmele
    Department of Urology, St Gallen Cantonal Hospital, St Gallen, Switzerland
    Urol Int 77:286-8. 2006
    ..We describe ureterolysis in two cases as a successful alternative approach...
  30. doi request reprint Nutrition, dietary supplements and adenocarcinoma of the prostate
    Christopher Schultz
    Cantonal Hospital of St Gallen, St Gallen, Switzerland
    Maturitas 70:339-42. 2011
    ..The trial was recently discontinued due to no evidence of benefit from either agent. Nevertheless, lifestyle changes can still be recommended for men at risk of developing clinical prostate cancer...
  31. doi request reprint Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters
    Hans Schiefer
    Department of Radiooncology, Cantonal Hospital St Gallen, St Gallen, Switzerland
    Strahlenther Onkol 185:689-95. 2009
    ..Therefore, thermoluminescence dosimeter (TLD) measurements on the index fingers and the backs of both hands were conducted...
  32. ncbi request reprint EAU guidelines on prostate cancer
    Axel Heidenreich
    Department of Urology, University Hospital Cologne, Cologne, Germany
    Eur Urol 53:68-80. 2008
    ..To present a summary of the 2007 version of the European Association of Urology (EAU) guidelines on prostate cancer (PCa)...
  33. ncbi request reprint First Report on Joint Use of a Da Vinci® Surgical System with Transfer of Surgical Know-How between Two Public Hospitals
    Agostino Mattei
    Klinik für Urologie, Kantonsspital Luzern, Lucerne, Switzerland
    Urol Int 93:1-9. 2014
    ..01). Conclusions: Da Vinci® device sharing with transfer of surgical know-how can reduce the costs of RARP without compromising surgical outcomes, even at the beginning of the learning curve. © 2014 S. Karger AG, Basel. ..
  34. doi request reprint Ciprofloxacin and epirubicin synergistically induce apoptosis in human urothelial cancer cell lines
    Daniel S Engeler
    Institute of Immunobiology, Cantonal Hospital of St Gallen, St Gallen, Switzerland daniel engeler kssg ch
    Urol Int 88:343-9. 2012
    ..To assess the potential role of combination therapy, cytotoxic effects of ciprofloxacin and epirubicin alone and in combination were determined...
  35. ncbi request reprint Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib
    Ralf Michael Fokt
    Department of Urology, Cantonal Hospital St Gallen, St Gallen, Switzerland
    Urol Int 83:122-4. 2009
    ..We present a case of a metastasis of renal cell carcinoma in the prostate which occurred 10 years after nephrectomy. Treatment with sunitinib was initiated and a notable response achieved...
  36. ncbi request reprint Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice
    György Söletormos
    Department of Clinical Biochemistry, Hillerød Hospital, Hillerød, Denmark
    Clin Chem 51:1342-51. 2005
    ..The European Group on Tumor Markers conducted a literature survey to determine both the magnitude and impact of biological variation on single, the mean of replicate, and serial tPSA measurements...
  37. ncbi request reprint Prostate biopsy in Central Europe: results of a survey of indication, patient preparation and biopsy technique
    Klaus G Fink
    Department of Urology and Andrology, Paracelsus Medical Private University, Salzburger Landeskliniken, Salzburg, Austria
    Urol Int 79:60-6. 2007
    ..We surveyed urologists in Austria, Germany and Switzerland regarding their standard approach to prostate biopsy...
  38. ncbi request reprint The rise and fall of PSA: clinical implications of prostate specific antigen kinetics
    Axel Semjonow
    Urol Res 30:85-8. 2002
  39. ncbi request reprint Spontaneous priapism after radical retropubic prostatectomy
    Dominik Bohlen
    Urology Center Berne, Berne, Switzerland
    Urol Int 77:182-3. 2006
    ..These episodes recurred several times during the next 3 weeks and then completely vanished. Pathophysiologically, we postulate intermittent position-depending venous obstruction due to local hematoma or thrombosis...